New research shows that the sustained expression of YES1, a member of the Src family of protein tyrosine kinases, plays an important role in the growth, viability and genomic stability of triple-negative breast cancer cells.
A new study of patients with early breast cancer suggests that the noninvasive assessment of sarcopenia using bioelectrical impedance analysis can help predict toxicity from adjuvant or neoadjuvant chemotherapy.
Multigene panel testing should be considered for all African-American women with triple-negative breast cancer regardless of their age or cancer history.
A new option proves effective for patients with HER2+ early breast cancer with residual disease after neoadjuvant therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Join experts from Cleveland Clinic and around the world at a CME-certified official review in Hollywood, Florida.
A new imaging modality may offer a wealth of prognostic information on tumor behavior and differentiation of cancer subtypes.
Cleveland Clinic oncologists conducted a new meta-analysis of breast cancer lumpectomy patients to determine the best margins to prevent additional surgery and optimize long-term survival.
Five-year follow-up data from the Prevention of Early Menopause Study shows use of goserelin, a gonadotropin hormone-releasing hor-mone agonist, along with standard chemotherapy, helps preserve fertility in women with breast cancer.
The first prospective randomized trial of scalp cooling shows that the therapy can significantly decrease chemotherapy-induced alopecia in breast cancer patients and is well tolerated.
As reported at the 2016 San Antonio Breast Cancer Symposium, results from NSABP B-42 trial contradicted previous studies and showed no benefit with letrozole use beyond five years. But investigators say longer followup is needed.